These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
595 related articles for article (PubMed ID: 18818047)
1. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047 [TBL] [Abstract][Full Text] [Related]
2. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related]
3. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326 [TBL] [Abstract][Full Text] [Related]
4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
5. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. Cui X; Zhou S; Xu H; Zhao T; Liu A; Guo X; Wang F Anticancer Drugs; 2009 Oct; 20(9):800-6. PubMed ID: 19606017 [TBL] [Abstract][Full Text] [Related]
6. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells. Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007 [TBL] [Abstract][Full Text] [Related]
7. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
8. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Ji BS; He L J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197 [TBL] [Abstract][Full Text] [Related]
9. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528 [TBL] [Abstract][Full Text] [Related]
10. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
11. Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line. Li J; Xu LZ; Yao JJ; Guo WJ; Xia P; Chen Y Acta Pharmacol Sin; 2001 Nov; 22(11):1023-7. PubMed ID: 11749795 [TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells. Sun LR; Zhong JL; Cui SX; Li X; Ward SG; Shi YQ; Zhang XF; Cheng YN; Gao JJ; Qu XJ Pharmacol Rep; 2010; 62(2):333-42. PubMed ID: 20508289 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents. Tang X; Gu X; Ren Z; Ma Y; Lai Y; Peng H; Peng S; Zhang Y Bioorg Med Chem Lett; 2012 Apr; 22(8):2675-80. PubMed ID: 22450134 [TBL] [Abstract][Full Text] [Related]
14. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Song YN; Guo XL; Zheng BB; Liu XY; Dong X; Yu LG; Cheng YN Toxicol In Vitro; 2011 Jun; 25(4):937-43. PubMed ID: 21402141 [TBL] [Abstract][Full Text] [Related]
15. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Shen J; Zhang W; Wu J; Zhu Y Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591 [TBL] [Abstract][Full Text] [Related]
16. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro. Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404 [TBL] [Abstract][Full Text] [Related]
18. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide. Wei HL; Wu YJ; Jing T; Bai DC; Ma LF Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281 [TBL] [Abstract][Full Text] [Related]
19. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348 [TBL] [Abstract][Full Text] [Related]
20. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G; Waxman DJ J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]